|The CD11a n/a (Catalog #MBS2534283) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Anti-Human CD11a Antibody (FITC conjugated) reacts with Human and may cross-react with other species as described in the data sheet.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis (The amount of the reagent is suggested to be used <= 0.5 ug /106 cells in 100 ul). Since applications vary, the appropriate dilutions must be determined for individual use. Researchers should empirically determine the suitability of the CD11a n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The CD11a (HI111) antibody recognizes the 180-kDa integrin alpha chain associated with CD18, the 95-kDa integrin beta2, which form heterodimer glycoprotein called the lymphocyte function antigen-1 (LFA-1, CD11a/CD18). Leukocytes express four CD11/CD18 integrins which include a common beta2 subunit and distinctive alpha chains. Besides CD11a/CD18, the other three integrins are known as CD11b/CD18, CD11c/CD18 and CD11d/CD18. LFA-1 is expressed on all leukocytes and is responsible for adhesion between leukocytes during immune response and transmigration of leukocytes across endothelium. The ligands for CD11a/CD18 are intercellular adhesion molecules CD54 (ICAM-1), CD102 (ICAM-2) and CD50 (ICAM-3). Patients bearing mutated CD18 genes do not express cell membrane LFA-1, a condition known as leukocyte adhesion deficiency 1 (LAD-1).
Conjugation: FITC. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD11a are readily searchable from our website. Different antibodies against the same target such as CD11a may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.